Convatec Group PLC
CTEC: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| ypW | LOCK|H^Qxp | LOCK|>Hz?X@ |
Convatec Earnings: Continence and Infusion Care Lift Sales and Guidance; Shares Undervalued
Convatec's organic sales growth (excluding InnovaMatrix) accelerated in the second half of 2026, delivering 6.6% for the 10 months ended October. Growth was driven by continence and infusion, with the latter also supporting margin expansion. The share price jumped 9% at the market open on Nov. 18.
